Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)	
Applicant/Patent Owner: Lek Pharmaceuticals d.d.	
Application No./Patent No.: 10/584,369 Filed/Issue Date: November 13, 2	2006
Titled: Synthesis Of Optically Pure(R)-5-(2-Amynopropyl)-2-Methoxybenzenesulphonamide	
Lek Pharmaceuticals d.d	
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university)	ilty, government agency, etc.
states that it is:	
1. X the assignee of the entire right, title, and interest in;	
2. an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is%); or	
3. the assignee of an undivided interest in the entirety of (a complete assignment from one of the jo	oint inventors was made)
the patent application/patent identified above, by virtue of either:	
An assignment from the inventor(s) of the patent application/patent identified above. The assign the United States Patent and Trademark Office at Reel 022406 , Frame 0023 copy therefore is attached.	nment was recorded in, or for which a
OR	
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current	
1. From: To:	
The document was recorded in the United States Patent and Trademark Office at	hereof is attached
Reel, Frame, or for which a copy to	
2. From: To:	
The document was recorded in the United States Patent and Trademark Office at	hannelte eur
Reel, Frame, or for which a copy t	
3. From: To:	
The document was recorded in the United States Patent and Trademark Office at	
Reel, Frame, or for which a copy t	thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet(s).	
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.	
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitt accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 3	ted to Assignment Division in 302.08}
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.	10-11 2000
M. 4001	Maich Wy
Signature \(\text{Signature} \)	Contine Contine
	Service Specialist Title
Printed or Typed Name	11/10

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/98 (01-09)
Approved for use through 02/28/2009. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number.

				STATEM	ENT	UNDER 37 C	FR 3.73	<u>3(b)</u>	-
Apr	olicant/	Patent Own	er: Lek Pharr	naceuticals d.d.	_				
				369		Filed	/Issue D	ate: Novem	ber 13, 2006
	Titled: Synthesis Of Optically Pure(R)-5-(2-Amynopropyl)-2-Methoxybenzenesulphonamide								
Lek	Pharr	maceutical	s d.d.	·	а	Corporation			
(Nan	ne of Ass	signee)		•		(Type of Assigned	e. e.g., com	oration, partners	hip, university, government agency, etc.
stat	les that	t it is:		•					,
1.	X	the assign	ee of the entire	right, title, and inte	rest i	n;			
2.		an assigne (The exter	ee of less than it (by percenta	the entire right, title, ge) of its ownership	and inter	interest in est is	%); o	r	
3.		the assign	ee of an undivi	ded interest in the e	ntire	ty of (a complete	assignr	ment from one	e of the joint inventors was made)
the	patent	application	/patent identifie	d above, by virtue o	of eith	ner:			
A.	X	the United	ment from the last states Patent states Patent	and Trademark Off	tent a	application/pate Reel 022406	nt identif	ied above. Ti , Frame 00	he assignment was recorded in 023 , or for which a
OR	}								
В.		A chain of	title from the in						the current assignee as follows:
		1. From:							
				was recorded in the					
			Reel	, F	rame	<u></u>	······································	or for which	a copy thereof is attached.
		2. From:							
				was recorded in the					
			Reel	, F	rame	9	······•	or for which	a copy thereof is attached.
		3. From:					To:		
			The document	was recorded in the	e Uni	ted States Pale	nt and Tr	ademark Offi	ce at
			Reel	, F	rame	9	•	or for which	n a copy thereof is attached.
		Additiona	al documents in	the chain of title ar	e liste	ed on a supplen	nental sh	eet(s).	
Σ	Or	concurrently	is being, subr	nitted for recordation	n pun	suant to 37 CFF	R 3.11.		ne original owner to the assignee was,
	ac	cordance wi	th 37 CFR Par	3, to record the as	signn	nent in the recor	ds of the	USPTO. <u>Se</u>	e submitted to Assignment Division in g MPEP 302.08]
Th	e unde	ersigned (wh	ose title is sup	olied below) is author	rizec	d to act on beha	if of the a	assignee.	24-03-09
-	S	ignature							Date
	G	illian McCa	ınn						Patent Service Specialist
l —	P	rinted or Ty	ped Name			· · · · · · · · · · · · · · · · · · ·			Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time genering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form end/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. MARK S. GRAHAM COMPANY: P.O. BOX 1871



UNITED STATES PATENT AND TRADEMARK OFFICE

Facsimile Transmission

To:

From:

Name:

MARK S. GRAHAM

Company:

P.O. BOX 1871 18655234478

Fax Number:

Voice Phone:

Name:

ASSIGNMENT SERVICES BRANCH

Voice Phone:

571-272-3350

37 C.F.R. 1.6 sets forth the types of correspondence that can be communicated to the Patent and Trademark Office via facsimile transmissions. Applicants are advised to use the certificate of facsimile transmission procedures when submitting a reply to a non-final or final Office action by facsimile (37 CFR 1.8(a)).

Fax Notes:

Pg# Description

Cover Page

439.TXT

Document 1, Batch 1600020

USPTO ASSIGNMENT SYSTEM PROCESSING

Date and time of transmission: Tuesday, March 17, 2009 5:21:28 PM

Number of pages including this cover sheet: 04

3/17/2009 5:21:51 PM PAGE 2/004 Fax Server

MARK S. GRAHAM COMPANY: P.O. BOX 1871



UNITED STATES PATENT AND TRADEMARK OFFICE

Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office



MARCH 17, 2009

USPTO

PTAS

MARK S. GRAHAM P.O. BOX 1871 KNOXVILLE, TN 37901

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT SERVICES BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 03/17/2009

REEL/FRAME: 022406/0023 NUMBER OF PAGES: 2

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 33577-US-PCT - 63946.US

ASSIGNOR:

MOHAR, BARBARA

DOC DATE: 06/19/2006

ASSIGNEE:

LEK PHARMACEUTICALS, D.D. VEROVSKOVA 57 1526 LJUBLJANA, SLOVENIA

SERIAL NUMBER: 10584369

FILING DATE: 11/13/2006

PATENT NUMBER: ISSUE DATE:

TITLE: SYNTHESIS OF OPTICALLY PURE(R)-5-(2-AMYNOPROPYL)-2-

METHOXYBENZ ENESULPHONAMIDE

USPTO 3/17/2009 5:21:51 PM PAGE 3/004 Fax Server

MARK S. GRAHAM COMPANY: P.O. BOX 1871

022406/0023 PAGE 2

ASSIGNMENT SERVICES BRANCH PUBLIC RECORDS DIVISION

The same management of the same of the sam

USPTO

Total Attachments: 1

source=63946us-tiouspto-20090317-ExecutedAssignment#page1.tif

3/17/2009 5:21:51 PM PAGE 4/004 Fax Server

MARK S. GRAHAM COMPANY: P.O. BOX 1871

PATENT ASSIGNMENT

Electronic Version v Stylesheet Version v	ENNANGATA						
SUBMISSION TYPE:		NEW ASSIGNMENT					
NATURE OF CONVE	YANCE:	ASSIGNMENT					
CONVEYING PARTY DATA							
		Name	Execution Date				
Barbara Mohar			06/19/2008				
RECEIVING PARTY (RECEIVING PARTY DATA						
Name:	Lek Pharmaceutic	als, d.d.					
Street Address:	Verovskova 57						
City:	1526 Ljubljana						
State/Country:	SLOVENIA						
PROPERTY NUMBER	RS Total: 1						
Property T	уре	Number					
Application Number:	105	14360					
		14000					
CORRESPONDENCE	E DATA						
Fax Number:	(885)523-44	78					
Fax Number: Correspondence will t	(885)523-44 be sent via US Mail	'8 when the fax attempt is unsuccessful.					
Fax Number: Correspondence will to Phone:	(865)523-44 be sent via US Mail 865-546-430	'8 when the fax attempt is unsuccessful. 5					
Fax Number: Correspondence will to Phone: Email:	(865)523-44' be sent via US Mall 865-546-430 mgraham@li	r8 when the fax attempt is unsuccessful. 5 ng-patent.com					
Fax Number: Correspondence will to Phone:	(885)523-44; be sent via US Mail 865-546-430 mgraham@li : Mark S. Grat P.O. Box 187	78 when the fax attempt is unsuccessful. 5 ng-patent.com am					
Fax Number: Correspondence will to Phone: Email: Correspondent Name	(885)523-44; be sent via US Mail 865-546-430 mgraham@li : Mark S. Grat P.O. Box 187	r8 when the fax attempt is unsuccessful. 5 ag-patent.com am					
Fax Number: Correspondence will to Phone: Email: Correspondent Name Address Line 1;	(885)523-44 be sent via US Mail 865-546-430 mgraham@li : Mark S. Grat P.O. Box 187 Knoxville, TE	78 when the fax attempt is unsuccessful. 5 ng-patent.com am					

<u>ASSIGNMENT</u>

I / We Barbara MOHAR, Kadunceva 1b, 1290 Grosuplje, Slovenia

for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, do hereby sell and assign to *Lek Pharmaceuticals d.d., a Company organized under the laws of Slovenia, of Verovskova 57, 1526 Ljubljana, Slovenia*, its successors, assigns and legal representatives all my/our right, title and interest, in and for the United States of America, in and to the invention entitled:

SYNTHESIS OF OPTICALLY PURE (R)-5-(2-AMYNOPROPYL)-2-METHOXYBENZENESULPHONAMIDE

invented by me/us and described in the international application

No. PCT/SI2004/000046

filed 27/12/2004

and all United States Letters Patent which may be granted therefor, and all divisions, reissues, continuations and extensions thereof, the said interest being the entire ownership of the said Letters Patent when granted, to be held and enjoyed by the said *Lek Pharmaceuticals d.d.*, its successors, assigns or other legal representatives, to the full end of the term for which said Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this assignment and sale had not been made;

And I/we hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent to the said *Lek Pharmaceuticals d.d.*.

Bailera Julia 19th of June 2006



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCY.
United States Patent and Trademark Office
Address COMMESSORE FOR PATENTS
FO Brillio
Artenta, Vigne 2011-110

CUSTOMER

NUMBER:

000083721

CORRESPONDENCE

ADDRESS:

Lek (Slovenia) - LUEDEKA, NEELY & GRAHAM, P.C. P.O. BOX 1871 Knoxviile, TN 37901

FAX:

PHONE:

865.5464305

E-MAIL:

MGRAHAM@LNG-PATENT.COM

Date Mailed: 10/20/2008

NOTICE OF CUSTOMER NUMBER ASSIGNMENT

The request to assign a "Customer Number" to the above-identified Correspondence Address and Practitioner Registration Number(s) indicated below has been accepted by the Commissioner of Patents and Trademarks.

The Customer Number as assigned above may be used to identify the correspondence address or "fee address" for, and/or the appointed practitioner(s) in, a United States patent application or patent.

PRACTITIONER REGISTRATION NUMBER(S) ASSIGNED TO THAT CUSTOMER NUMBER:

22667, 24233, 28730, 28979, 32355, 34165, 34369, 34940 39596, 44990, 47507, 47601, 48633, 51975, 52646, 58753 58947, 61472.

Patents Electronic Business Center 866-217-9197 (toll-free) or 571-272-4100

PART I - ATTORNEY/APPLICANT COPY